Indication · Cardiology
Tricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
77
Cleared or approved since 2000
PMA and De Novo
31
Higher-risk or first-of-kind devices
Breakthrough devices
2
Authorized through June 30, 2026
Recruiting device trials
48
129 device trials in all
Breakthrough-designated devices
- Edwards EVOQUE Tricuspid Valve Replacement SystemEdwards Lifesciences, LLC · 2025
1 more devices with a free account
Devices
77 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic Valve
Edwards Lifesciences, LLC · PMA · Heart-Valve, Non-Allograft Tissue · newest 2022 · 6 decisions
59 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart DiseaseActive, not recruiting
Queen Mary University of LondonAcademic, hospital or other
NCT05064514 · 15 participants (planned) · Start Apr 6, 2022 · Primary completion May 21, 2028
Device: Transcatheter Tricuspid Valved Stent Graft · For: Tricuspid Regurgitation; Tricuspid Valve Disease; Carcinoid Syndrome and 1 more
Sites: London, United Kingdom
128 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on tricuspid regurgitation across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.